In the first approach of its kind, San Diego-based Fate Therapeutics will begin testing a small molecule drug in combination with stem cells extracted from cord blood to see whether the approach can replenish the blood systems in people with leukemia and lymphoma during standard transplant therapy...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129